Neurosciences
Neurovascular Diseases
Joan Montaner Villalonga
Principal investigators José Álvarez Sabin, Maria Pilar Delgado Martínez, Israel Fernández Cadenas, Maria Mar Hernandez Guillamon, Carlos Molina Cateriano, Jorde Pagola Pérez Blanca, Marc Ribó Jacobi, Anna Rosell Novel, Marta A Rubiera Del Fueyo | Researchers Teresa Garcia Berrocoso, Yolanda Riba Llena, David Rodríguez Luna, Estevo Santamarina Pérez | Researchers in training Alejandro Bustamante Rangel, Caty Carrera Vasconez, Sogia Fernandez de Re Alda, Marina Gabriel Salazar, Alba Simats Oriol, Nuria Paz Torres Aguila | Nursing, technical and administrative staff Laura Abraira del Fresno, Cristina Boada Llamas, Sandra Boned Riera, Elizabeth Calva Simbaña, Carole Conforti, Natalia Corbeto Lopez, Dolors Giralt Casellas, Dolors Giralt Casellas, Jesus Maria Juega Mariño, Gonzalo Pablo Mazuela Aguila, Alex Montañola Pujol, Estefania Montiel, Mª Angeles Muchada López, Anna Penalba Morenilla, Manuel Quintana Luque, Silvia Ruiz Álvarez, Javier Sánchez López, Mireia Sanchis Marin, Estela Sanjuan Menendez, Katherine El Santana Roman
Summary
The clinicians of the study REVASCAT (published in the NEJM) have demonstrated that mechanical thrombectomy in the first 8h after stroke improves disability.
In order to improve thrombolytic therapy safety, we have shown that the plasmatic determination of the nuclear receptor NURR1 before the r-tPA administration can predict hemorrhagic complications.
We have ended the StrokeChip study to diagnose stroke by means of a blood test. With 1,325 recruited patients it is the most wide stroke population ever recruited worldwide.
In collaboration with the neurorehabilitation area of the HUVH we have shown that MMP-3 is increased after the rehabilitation therapy in patients with better motor and functional recovery. Experimentally we have demonstrated that MMP-13 is involved in the infarct development and tissular reorganization.